Literature DB >> 31696465

Effects of LncRNA KCNQ1OT1 on proliferation and migration of ovarian cancer cells by Wnt/β-catenin.

Z-P Luo1, H Jin.   

Abstract

OBJECTIVE: To explore the role of long noncoding ribonucleic acid (lncRNA) KCNQ1OT1 in the proliferation, apoptosis, and migration of ovarian cancer cells via Wnt/β-catenin.
MATERIALS AND METHODS: Ovarian cancer A2780 cells were divided into three groups, namely control group, KCNQ1OT1 overexpression group, and KCNQ1OT1 knockdown group. Next, the effect of KCNQ1OT1 on the proliferation of ovarian cancer A2780 cells was detected by cell counting kit-8 (CCK-8) assay. Wound healing assay and transwell assay were carried out to determine the influence of KCNQ1OT1 on the migration ability of ovarian cancer A2780 cells. The role of KCNQ1OT1 in the cell cycle of ovarian cancer A2780 cells was detected via flow cytometry. The impact of KCNQ1OT1 on the expression level of β-catenin protein in ovarian cancer A2780 cells was determined through Western blotting and fluorescence immunoassay.
RESULTS: The proliferation rate of cells was overtly decreased in KCNQ1OT1 knockdown group but significantly increased in KCNQ1OT1 overexpression group. The results of both wound healing and transwell assays showed that the migration ability of cells was reduced in KCNQ1OT1 knockdown group but raised in KCNQ1OT1 overexpression group. According to flow cytometry, the cell cycle was clearly arrested in the G0/G1 phase in KCNQ1OT1 knockdown group. The results of Western blotting and fluorescence immunoassay revealed that compared with that in control group, the expression level of β-catenin protein evidently declined in KCNQ1OT1 knockdown group, but it was notably elevated in KCNQ1OT1 overexpression group.
CONCLUSIONS: Increased lncRNA KCNQ1OT1 in ovarian cancer cells promotes the expression of β-catenin, thereby facilitating the proliferation and migration of ovarian cancer cells.

Entities:  

Year:  2019        PMID: 31696465     DOI: 10.26355/eurrev_201910_19273

Source DB:  PubMed          Journal:  Eur Rev Med Pharmacol Sci        ISSN: 1128-3602            Impact factor:   3.507


  7 in total

Review 1.  LncRNAs in Ovarian Cancer Progression, Metastasis, and Main Pathways: ceRNA and Alternative Mechanisms.

Authors:  Eleonora A Braga; Marina V Fridman; Alexey A Moscovtsev; Elena A Filippova; Alexey A Dmitriev; Nikolay E Kushlinskii
Journal:  Int J Mol Sci       Date:  2020-11-23       Impact factor: 5.923

2.  LncRNA-MSC-AS1 inhibits the ovarian cancer progression by targeting miR-425-5p.

Authors:  Yinling Zhao; Xinhua Bu; Donglan Yuan; Dandan Zhu; Tianhui Xu; Aihua Huang; Li Jiang; Chiwen Liu; Hua Qian
Journal:  J Ovarian Res       Date:  2021-08-28       Impact factor: 4.234

Review 3.  KCNQ1OT1: An Oncogenic Long Noncoding RNA.

Authors:  Patrice Cagle; Qi Qi; Suryakant Niture; Deepak Kumar
Journal:  Biomolecules       Date:  2021-10-29

4.  Long non-coding RNA KCNQ1OT1 facilitates the progression of cervical cancer and tumor growth through modulating miR-296-5p/HYOU1 axis.

Authors:  Jun Liu; Yingmei Wang
Journal:  Bioengineered       Date:  2021-12       Impact factor: 3.269

5.  The LINC00922 aggravates ovarian cancer progression via sponging miR-361-3p.

Authors:  Liping Wang; Chenchen Ren; Yajuan Xu; Li Yang; Yannan Chen; Yuanhang Zhu
Journal:  J Ovarian Res       Date:  2021-06-11       Impact factor: 4.234

6.  lncRNA KCNQ1OT1 promotes proliferation and invasion of glioma cells by targeting the miR‑375/YAP pathway.

Authors:  Panfeng Ding; Bo Liang; Jixin Shou; Xinjun Wang
Journal:  Int J Mol Med       Date:  2020-10-19       Impact factor: 4.101

7.  Inhibition of lncRNA KCNQ1OT1 Improves Apoptosis and Chemotherapy Drug Response in Small Cell Lung Cancer by TGF-β1 Mediated Epithelial-to-Mesenchymal Transition.

Authors:  Deyu Li; Qin Tong; Yuane Lian; Zhizhong Chen; Yaru Zhu; Weimei Huang; Yang Wen; Qiongyao Wang; Shumei Liang; Man Li; Jianjing Zheng; Zhenhua Liu; Huanxin Liu; Linlang Guo
Journal:  Cancer Res Treat       Date:  2021-03-09       Impact factor: 4.679

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.